Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma

被引:3
|
作者
Fernandez-miranda, Ismael [1 ]
Pedrosa, Lucia [1 ]
Gonzalez-Rincon, Julia [1 ,2 ]
Espinet, Blanca [3 ,4 ]
Vicente, Fatima de la Cruz [5 ]
Climent, Fina [6 ]
Gomez, Sagrario [1 ]
Royuela, Ana [7 ]
Camacho, Francisca I. [8 ]
Martin-Acosta, Paloma [9 ]
Yanguas-Casas, Natalia [1 ,10 ]
Dominguez, Marina [1 ]
Mendez, Miriam [1 ,11 ]
Colomo, Luis [3 ]
Salar, Antonio [11 ,12 ]
Horcajo, Beatriz [1 ]
Navarro, Marta [1 ]
Garcia-Cosio, Monica [12 ,13 ]
Piris-Villaespesa, Miguel [13 ,14 ]
Llanos, Marta [14 ,15 ]
Garcia, Juan F. [16 ]
Sequero, Silvia [16 ,17 ]
Mercadal, Santiago [17 ,18 ]
Garcia-Hernandez, Sonia [19 ]
Navarro, Belen [20 ]
Mollejo, Manuela [21 ]
Provencio, Mariano [1 ,22 ]
Sanchez-Beato, Margarita [1 ]
机构
[1] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Lymphoma Res Grp, IDIPHISA, Majadahonda, Madrid, Spain
[2] Fujitsu Technol Solut SA, CoE Data Intelligence, Camino Cerro Gamos 1,Pozuelo Alarcon, Madrid, Spain
[3] Inst Hosp Mar Investigac Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain
[4] Hosp del Mar, Dept Pathol, Barcelona, Spain
[5] Univ Seville, Univ Hosp Virgen Rocio, Dept Hematol, Inst Biomed Sevilla IBIS CSIC CIBERONC, Seville, Spain
[6] Hosp Univ Bellvitge, Dept Pathol, IDIBELL, Barcelona, Spain
[7] Hosp Univ Puerta Hierro Majadahonda, Biostat Unit, IDIPHISA, CIBERESP, Madrid, Spain
[8] Hosp Univ Getafe, Dept Pathol, Madrid, Spain
[9] Hosp Univ Puerta Hierro Majadahonda, Dept Pathol, Canc Mol Pathol Grp, IDIPHISA, Majadahonda, Madrid, Spain
[10] Ctr Invest Biomed Red Fragil & Envejecimiento Salu, Madrid, Spain
[11] Hosp Univ Puerta HierroMajadahonda, Dept Med Oncol, IDIPHISA, Madrid, Spain
[12] Hosp del Mar, Dept Hematol, Barcelona, Spain
[13] Hosp Univ Ramon y Cajal, Dept Pathol, Madrid, Spain
[14] Hosp Univ Ramon y Cajal, Dept Hematol, Madrid, Spain
[15] Hosp Univ Canarias, Dept Oncol, Tenerife, Spain
[16] Hosp MD Anderson Canc Ctr, Dept Pathol, Madrid, Spain
[17] Hosp Univ San Cecilio, Dept Oncol, Granada, Spain
[18] Hosp Duran i Reynals, Dept Hematol, ICO, Barcelona, Spain
[19] Hosp Univ Canarias, Dept Pathol, Tenerife, Spain
[20] Hosp Univ Puerta Hierro, Dept Hematol, Majadahonda, Madrid, Spain
[21] Complejo Hosp Toledo, Dept Pathol, Toledo, Spain
[22] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Fac Med, Dept Med Oncol, Majadahonda, Madrid, Spain
关键词
follicular lymphoma; genomics; histologic transformation; predictive model; PROGNOSTIC INDEX FLIPI; 1ST-LINE IMMUNOCHEMOTHERAPY; TNFRSF14; MUTATIONS; EARLY PROGRESSION; SURVIVAL; GENETICS; OUTCOMES; RITUXIMAB; ERA;
D O I
10.1016/j.modpat.2024.100516
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Follicular lymphoma (FL) is the most frequent indolent lymphoma. Some patients (10%-15%) experience histologic transformation (HT) to a more aggressive lymphoma, usually diffuse large Bcell lymphoma (DLBCL). This study aimed to validate and improve a genetic risk model to predict HT at diagnosis.We collected mutational data from diagnosis biopsies of 64 FL patients. We combined them with the data from a previously published cohort (total n 1/4 104; 62 from nontransformed and 42 from patients who did transform to DLBCL). This combined cohort was used to develop a nomogram to estimate the risk of HT. Prognostic mutated genes and clinical variables were assessed using Cox regression analysis to generate a risk model. The model was internally validated by bootstrapping and externally validated in an independent cohort. Its performance was evaluated using a concordance index and a calibration curve. The clinicogenetic nomogram included the mutational status of 3 genes (HIST1HE1, KMT2D, and TNFSR14) and high-risk Follicular Lymphoma International Prognostic Index and predicted HT with a concordance index of 0.746. Patients were classified as being at low or high risk of transformation. The probability HT function at 24 months was 0.90 in the low-risk group vs 0.51 in the high-risk group and, at 60 months, 0.71 vs 0.15, respectively. In the external validation cohort, the probability HT function in the low-risk group was 0.86 vs 0.54 in the high-risk group at 24 months, and 0.71 vs 0.32 at 60 months. The concordance index in the external cohort was 0.552. In conclusion, we propose a clinicogenetic risk model to predict FL HT to DLBLC, combining genetic alterations in HIST1H1E, KMT2D, and TNFRSF14 genes and clinical features (Follicular Lymphoma International Prognostic Index) at diagnosis. This model could improve the management of FL patients and allow treatment strategies that would prevent or delay transformation. (c) 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Development and External Validation of a Lymphoma-Specific Venous Thromboembolism Risk Assessment Model
    Ma, Shengling
    Swinnerton, Kaitlin N.
    La, Jennifer
    Guffey, Danielle
    Bandyo, Raka
    Amos, Christopher I.
    Chitalia, Vipul
    De Las Pozas, Giordana
    Toale, Katy M.
    Xiao, Xiangjun
    Hernandez, Cristhiam M. Rojas
    Ravid, Katya
    Merriman, Kelly
    Flowers, Christopher R.
    Fillmore, Nathanael R.
    Li, Ang
    BLOOD, 2023, 142
  • [32] SOMATIC MUTATIONS IN TRANSLOCATED BCL-2 GENE ASSOCIATED WITH HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA
    CASALI, P
    MATOLCSY, A
    WARNKE, R
    KNOWLES, DM
    FASEB JOURNAL, 1995, 9 (03): : A123 - A123
  • [33] LONG-TERM SURVIVAL AFTER HISTOLOGIC TRANSFORMATION OF LOW-GRADE FOLLICULAR LYMPHOMA
    YUEN, AR
    KAMEL, OW
    HALPERN, J
    HORNING, SJ
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) : 1726 - 1733
  • [34] First external validation of the FLIPI-L score in a single-center series of patients with follicular lymphoma
    Mozas, Pablo
    Rivero, Andrea
    Rivas-Delgado, Alfredo
    Correa, Juan Gonzalo
    Condom, Maria
    Nadeu, Ferran
    Gine, Eva
    Delgado, Julio
    Villamor, Neus
    Campo, Elias
    Magnano, Laura
    Lopez-Guillermo, Armando
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) : 297 - 301
  • [35] Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma
    Luttwak, Efrat
    Qiu, Annie
    Okwali, Michelle
    Rivas-Delgado, Alfredo
    Isgor, Irem
    Boardman, Alexander P.
    Caron, Philip
    David, Kevin A.
    Falchi, Lorenzo
    Ghione, Paola
    Hamlin, Paul A.
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Johnson, William
    Kumar, Anita
    Lue, Jennifer Kimberly
    Moskowitz, Alison
    Noy, Ariela
    Galera, Pallavi
    Palomba, M. Lia
    Stuver, Robert
    Torka, Pallawi
    Vardhana, Santosha A.
    Zelenetz, Andrew D.
    Schoder, Heiko
    Yahalom, Joachim
    Dogan, Ahmet
    Salles, Gilles
    BLOOD, 2023, 142
  • [36] External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients
    Rosenberg, David J.
    Press, Anne
    Fishbein, Joanna
    Lesser, Martin
    McCullagh, Lauren
    McGinn, Thomas
    Spyropoulos, Alex C.
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (03) : 530 - 536
  • [37] Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma
    Zha, Jie
    Chen, Qinwei
    Zhang, Wei
    Jing, Hongmei
    Ye, Jingjing
    Yu, Haifeng
    Yi, Shuhua
    Li, Caixia
    Zheng, Zhong
    Xu, Wei
    Li, Zhifeng
    Ping, Lingyan
    He, Xiaohua
    Zhang, Liling
    Xie, Ying
    Chen, Feili
    Sun, Xiuhua
    Su, Liping
    Zhang, Huilai
    Lin, Zhijuan
    Yang, Haiyan
    Zhao, Weili
    Qiu, Lugui
    Li, Zhiming
    Song, Yuqin
    Xu, Bing
    BLOOD, 2023, 142
  • [38] VALIDATION OF A MULTIVARIABLE TROMBOTOUS RISK MODEL IN PATIENTS WITH LYMPHOMA. RISK SCALE THROLY
    Garcia Raso, A.
    Penedo Coello, A.
    Castano Bonilla, T.
    Alonso Dominguez, J.
    Arquero Portero, T.
    Cordoba Mascunano, R.
    Vidal Laso, R.
    Llamas Sillero, P.
    HAEMATOLOGICA, 2017, 102 : 228 - 229
  • [39] Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma
    Montoto, Silvia
    Davies, Andrew John
    Matthews, Janet
    Calaminici, Maria
    Norton, Andrew J.
    Amess, John
    Vinnicombe, Sarah
    Waters, Rachel
    Rohatiner, Ama Z. S.
    Lister, T. Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) : 2426 - 2433
  • [40] Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma
    Reagan, Patrick M.
    Kelly, Jennifer L.
    Baran, Andrea
    Barr, Paul M.
    Casulo, Carla
    Chengazi, Vaseem
    Friedberg, Jonathan W.
    BLOOD, 2014, 124 (21)